| Literature DB >> 29898386 |
Patricio Opazo1, Silvia Viana da Silva2, Mario Carta2, Christelle Breillat2, Steven J Coultrap3, Dolors Grillo-Bosch2, Matthieu Sainlos2, Françoise Coussen2, K Ulrich Bayer3, Christophe Mulle2, Daniel Choquet4.
Abstract
Alzheimer's disease (AD) is emerging as a synaptopathology driven by metaplasticity. Indeed, reminiscent of metaplasticity, oligomeric forms of the amyloid-β peptide (oAβ) prevent induction of long-term potentiation (LTP) via the prior activation of GluN2B-containing NMDA receptors (NMDARs). However, the downstream Ca2+-dependent signaling molecules that mediate aberrant metaplasticity are unknown. In this study, we show that oAβ promotes the activation of Ca2+/calmodulin-dependent kinase II (CaMKII) via GluN2B-containing NMDARs. Importantly, we find that CaMKII inhibition rescues both the LTP impairment and the dendritic spine loss mediated by oAβ. Mechanistically resembling metaplasticity, oAβ prevents subsequent rounds of plasticity from inducing CaMKII T286 autophosphorylation, as well as the associated anchoring and accumulation of synaptic AMPA receptors (AMPARs). Finally, prolonged oAβ treatment-induced CaMKII misactivation leads to dendritic spine loss via the destabilization of surface AMPARs. Thus, our study demonstrates that oAβ engages synaptic metaplasticity via aberrant CaMKII activation.Entities:
Keywords: AMPAR; APP; Alzheimer’s disease; CaMKII; GluN2B; LTP; NMDAR; dendritic spines; long-term potentiation; metaplasticity; oligomeric Aβ
Mesh:
Substances:
Year: 2018 PMID: 29898386 PMCID: PMC6089247 DOI: 10.1016/j.celrep.2018.05.036
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423